SEC Filing Summary: Tharimmune, Inc. (THAR)
Business Context and Reporting Period
This Form 8-K was filed by Tharimmune, Inc. on April 25, 2025, reporting events occurring on April 24, 2025. The registrant is a Delaware corporation listed on The Nasdaq Stock Market LLC under the symbol "THAR" and is classified as an emerging growth company.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance events and does not contain financial performance data.
Material Changes
The primary material change reported is the departure of two directors from the Board of Directors. Leonard Mazur and Lynne Bui, MD, have notified the Board that they will not seek re-election and will retire effective June 10, 2025, at the Company's 2025 Annual Meeting of Stockholders.
Management Commentary and Risks
Management explicitly stated that the retirements of Mr. Mazur and Dr. Bui do not relate to any disagreements with the Company, its management, or the Board of Directors. No other risks, contingencies, or unusual items were disclosed in this filing.
Key Facts for Investor Verification
- Leonard Mazur and Lynne Bui, MD, are retiring from the Board of Directors.
- The effective date of retirement is June 10, 2025.
- The departures are voluntary and not related to any disputes with the company.
- The filing contains no financial data or updated guidance.